Search alternatives:
significantly linked » significantly longer (Expand Search), significantly altered (Expand Search), significantly higher (Expand Search)
largest decrease » marked decrease (Expand Search)
linked decrease » marked decrease (Expand Search), linear decrease (Expand Search)
larger decrease » marked decrease (Expand Search)
Showing 61 - 80 results of 2,438 for search '(( significantly linked decrease ) OR ( significant ((larger decrease) OR (largest decrease)) ))', query time: 0.55s Refine Results
  1. 61
    Trust levels before and after the COVID-19 pandemic (n = 10,000).

    Trust levels before and after the COVID-19 pandemic (n = 10,000). by Alain Abi-Rizk (8549358)

    Published 2025
    Save to List
    Saved in:
  2. 62
    No significant differences in the numbers of eggs between Mst1<sup>+/+</sup> and Mst1<sup>ΔM/ΔM</sup> mice.

    No significant differences in the numbers of eggs between Mst1<sup>+/+</sup> and Mst1<sup>ΔM/ΔM</sup> mice. by Jianyang Li (461703)

    Published 2024
    Save to List
    Saved in:
  3. 63
    Bar charts showing the numbers of significantly differentially expressed genes for the different contrasts.

    Bar charts showing the numbers of significantly differentially expressed genes for the different contrasts. by Gillian P. McHugo (8965919)

    Published 2025
    Save to List
    Saved in:
  4. 64
    A. Representative data of NB4 cells (treated with LPS and RSV) ETOsis percentage by Flow cytometry method. NB4 cells are stimulated with LPS (1). NB4 cells are treated with 5 µ M RSV (2). NB4 cells are treated with 10 µ M RSV. **p < 0.01. In comparison to the condition in which the cells were treated with the stimulant (LPS) alone, 5 and 10 μM resveratrol significantly reduced ETosis. B. Results of flowcytometry analysis.

    A. Representative data of NB4 cells (treated with LPS and RSV) ETOsis percentage by Flow cytometry method. NB4 cells are stimulated with LPS (1). NB4 cells are treated with 5 µ M R... by Mahshid Vafajoo (21144147)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 65
    Change in Watt’s Connectedness Scale, Subscales by Treatment Group.

    Change in Watt’s Connectedness Scale, Subscales by Treatment Group. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 66
    Primary and secondary efficacy end points (intention-to-treat population).

    Primary and secondary efficacy end points (intention-to-treat population). by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 67
    Demographic and clinical characteristics of participants at baseline.

    Demographic and clinical characteristics of participants at baseline. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 68
    Study-related adverse events.

    Study-related adverse events. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 69
    Study flow chart.

    Study flow chart. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 70
    Change in QIDS-SR-16 and MBI-HSS-MP by Treatment Group.

    Change in QIDS-SR-16 and MBI-HSS-MP by Treatment Group. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 71
    Study CONSORT diagram.

    Study CONSORT diagram. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 72
    Change in Demoralization Scale (DSII) by Treatment Group.

    Change in Demoralization Scale (DSII) by Treatment Group. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 73
    Change in Watt’s Connectedness Scale (WCS), General Connectedness by Treatment Group.

    Change in Watt’s Connectedness Scale (WCS), General Connectedness by Treatment Group. by Benjamin R. Lewis (22279166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 74
    Supporting information.

    Supporting information. by Yu Sang Choi (22656230)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 75
    PCoA plot analysis for dissimilarity.

    PCoA plot analysis for dissimilarity. by Yu Sang Choi (22656230)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 76
    Composition of the gut microbiota at the genus level following the administration of MP.

    Composition of the gut microbiota at the genus level following the administration of MP. by Yu Sang Choi (22656230)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 77
    Disruption of hepatic metabolism in Lep KO mice.

    Disruption of hepatic metabolism in Lep KO mice. by Yu Sang Choi (22656230)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 78
    Composition of the gut microbiota at the phylum level following the administration of MP.

    Composition of the gut microbiota at the phylum level following the administration of MP. by Yu Sang Choi (22656230)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 79
    Comparison of (a) Chao index and (b) Shannon diversity index of the fecal microbiota in WT and Lep KO mice.

    Comparison of (a) Chao index and (b) Shannon diversity index of the fecal microbiota in WT and Lep KO mice. by Yu Sang Choi (22656230)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 80
    KEGG pathway enrichment bubble map of the top 20 DAPs.

    KEGG pathway enrichment bubble map of the top 20 DAPs. by Caijin Chen (3107787)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: